Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday.

Several other analysts also recently commented on the company. Weiss Ratings downgraded Theravance Biopharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. BTIG Research reissued a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a research note on Friday, March 20th. Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 19th. HC Wainwright increased their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, B. Riley Financial increased their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Theravance Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $21.83.

Theravance Biopharma Stock Performance

TBPH stock opened at $16.50 on Tuesday. The stock’s 50 day simple moving average is $16.69 and its 200 day simple moving average is $17.09. Theravance Biopharma has a fifty-two week low of $8.31 and a fifty-two week high of $21.03. The company has a market cap of $849.63 million, a P/E ratio of 8.13 and a beta of 0.17.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors have recently modified their holdings of TBPH. Quarry LP bought a new position in shares of Theravance Biopharma in the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 515 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 781 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 4,662 shares in the last quarter. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.